Comparative safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation: A network meta-analysis.
J Formos Med Assoc
; 2023 Nov 22.
Article
em En
| MEDLINE
| ID: mdl-37996330
ABSTRACT
BACKGROUND:
The introduction of non-vitamin K antagonist oral anticoagulants (NOACs), with a non-inferior or superior clinical efficacy profile compared to vitamin K antagonists (VKAs), has significantly improved the safety profile and treatment adherence of patients with non-valvular atrial fibrillation (AF). However, few studies have compared the effectiveness and safety of NOACs. Therefore, we conducted this systematic review and network meta-analysis to compare the safety and clinical effectiveness of NOACs and VKAs in patients with non-valvular AF.METHODS:
An online bibliographic search was conducted to retrieve real-world evidence studies published between January 2019 and June 2022.RESULTS:
Dabigatran was associated with lower risks of major bleeding, ischemic stroke, and intracranial hemorrhage than warfarin. Among the NOACs, only dabigatran had a lower risk of all-cause mortality than warfarin. Dabigatran was also associated with lower risks of major bleeding and intracranial hemorrhage than rivaroxaban.CONCLUSION:
Our meta-analysis confirms that dabigatran's real-world safety and clinical effectiveness align with the results of pivotal clinical trials.
Texto completo:
1
Base de dados:
MEDLINE
Tipo de estudo:
Systematic_reviews
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article